Patritumab Human Anti-ERBB3 Recombinant Antibody|cas:1262787-83-6|西域试剂

Patritumab Human Anti-ERBB3 Recombinant Antibody,98.94%

产品编号：Bellancom-P99275| CAS NO：1262787-83-6

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99275		￥3900.00	杭州北京（现货）
Bellancom-P99275		￥9750.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Patritumab Human Anti-ERBB3 Recombinant Antibody

产品介绍

Patritumab (Human Anti-ERBB3 Recombinant Antibody) 是针对 ERBB3 的中和性单克隆抗体。Patritumab与 Cetuximab (HY-P9905) 具有协同作用，可有效抑制 EGFR，HER2，HER3，ERK 和 AKT 的磷酸化。Patritumab 也能诱导细胞凋亡 (apoptosis)，也抑制胰腺、非小细胞肺癌和结直肠癌异种移植物肿瘤的生长。

生物活性

Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors.

体外研究

Patritumab targets to the extracellular domain (ECD) of HER3 and (10 μg/mL; 5 d) induces DiFi-HRG4 cells apoptosis.
Patritumab (10 μg/mL; 6 h) markedly inhibits the phosphorylation of HER3 and AKT, without affecting that of ERK, in DiFi-HRG4 cells.
Patritumab (10 μg/mL; 48 h) also induces the cleavage of PARP accompanied with both up-regulation of BIM and down-regulation of survivin expression.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	DiFi-HRG cells
Concentration:	10 μg/mL
Incubation Time:	6 hours
Result:	Inhibited the phosphorylation of HER3 and AKT as well as down-regulated survivin expression.

体内研究
(In Vivo)

Patritumab (1 mg/mouse; i.p.; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity in DiFi-HRG tumor xenografts model in mice.
Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and that combination therapy with cetuximab and patritumab overcomes such resistance in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female athymic nude mice (BALB/c; 5-6 weeks old) with DiFi-Mock1 or DiFi-HRG4 (s.c.)
Dosage:	1 mg/body
Administration:	Intraperitoneal injection; twice a week for 4 weeks
Result:	Individual Patritumab treatment had little effect on the growth of tumors formed by either cell line. Combination of Cetuximab and Patritumab induced substantial regression of DiFi-HRG4 xenografts.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female athymic nude mice (BALB/c; 5-6 weeks old) with DiFi-Mock1 or DiFi-HRG4 (s.c.)
Dosage:	1 mg/body
Administration:	Intraperitoneal injection; twice a week for 4 weeks
Result:	Individual Patritumab treatment had little effect on the growth of tumors formed by either cell line. Combination of Cetuximab and Patritumab induced substantial regression of DiFi-HRG4 xenografts.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female athymic nude mice (BALB/c; 5-6 weeks old) with DiFi-Mock1 or DiFi-HRG4 (s.c.)
Dosage:	1 mg/body
Administration:	Intraperitoneal injection; twice a week for 4 weeks
Result:	Individual Patritumab treatment had little effect on the growth of tumors formed by either cell line. Combination of Cetuximab and Patritumab induced substantial regression of DiFi-HRG4 xenografts.